Third, the more significant improvement in obesity‐related biomarkers and adipocytokine levels, such as C‐reactive protein and tumor necrosis factor‐alpha, among females compared with males undergoing GLP‐1 RA therapy potentially explains their enhanced effectiveness in achieving weight reduction because a decrease in these markers may be linked to the observed weight loss, which is known to contribute to sex‐based differences in weight reduction outcomes [2]. The gene discussed is GLP1R; the disease is Obesity.